Is Takeda’s pursuit of Irish rare disease drug group Shire over even before it has properly begun? BorrowThat was after a deal worth just over $5 billion (€4 billion). Analysts have suggested it would make more sense for Takeda to purchase parts of Shire’s business rather than the whole group but that moment may well have passed now. Certainly the view among Japanese analysts is that a full acquisition of Shire is beyond Takeda. The problem for Flemming Ornskov and his team at Shire is that the public declaration of interest means they are now in the crosshairs.

Source: The Irish Times March 31, 2018 05:03 UTC